Key result
Intravenous lidocaine significantly reduced baseline cardiac sympathetic nervous activity by 23% (p<0.001) and decreased activity during ventricular fibrillation by 52% (p<0.001) in dogs.
Why the study?
Does intravenous lidocaine reduce cardiac sympathetic nervous activity during myocardial ischemia, reperfusion, and ventricular fibrillation in open-chest dogs?
Does intravenous lidocaine reduce cardiac sympathetic nervous activity during myocardial ischemia, reperfusion, and ventricular fibrillation in open-chest dogs?
p-value: p=<0.001
Intravenous lidocaine significantly attenuates cardiac sympathetic nervous activity during baseline and ventricular fibrillation in a canine model of ischemia and reperfusion.
Hypothesis-generating for lidocaine sympatholysis in ischemia; human trials needed before any clinical consideration.
In 12 open-chest dogs, cardiac sympathetic nervous activity (CSNA) was recorded before and after occlusion of the left anterior descending coronary artery as well as during reperfusion and ventricular fibrillation (VF). In 7 control animals, CSNA did not significantly differ from preocclusion levels when determined 20 min after occlusion (+3.5 +/- 1.5%, mean +/- SEM) and up to 15 min following reperfusion (+1.5 +/- 0.6%). However, VF was associated with a potential increase in CSNA by 106 +/- 15.5% (p less than 0.001). The effect of lidocaine (6 mg/kg) on cardiac sympathetic tone was examined in 5 additional animals. Lidocaine reduced control CSNA by 23 +/- 4.7% (p less than 0.001); subsequent ischemia and reperfusion did not substantially change the level of preocclusion activity. CSNA decreased significantly also during VF (52 +/- 4.2%, p less than 0.001). In conclusion, efferent CSNA was slightly altered in the course of acute myocardial ischemia and reperfusion, but significantly increased during VF. Lidocaine produced marked attenuation of CSNA in anesthetized dogs.
No takes yet. Share an insight, caveat, or question.
Aidonidis et al. (2008) studied Myocardial ischemia, reperfusion, and ventricular fibrillation (n=12). Intravenous Lidocaine vs. Control (no lidocaine) was evaluated on Cardiac sympathetic nervous activity (CSNA) (p=<0.001). Intravenous lidocaine significantly reduced baseline cardiac sympathetic nervous activity by 23% (p<0.001) and decreased activity during ventricular fibrillation by 52% (p<0.001) in dogs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: